Pharmaceuticals

After a Health Canada-mandated pause, LSL's Steri-Med is near full remediation. This is more than a fix—it’s a calculated play for North American market leadership.

Australian biotech Immuron hires a top dealmaker to land a partner for its novel C. diff therapy. The goal: secure funding and unlock a potential $400M market.

UK biotech Ananda Pharma advances its MRX1 drug to Phase 2 trials, targeting a debilitating chemotherapy side effect with no current effective treatment.

Novartis's acquisition of Myricx Bio isn't just a deal. It's a story of academic grit, venture capital vision, and a new blueprint for patient-centric cancer therapy.

A new partnership aims to use tiny, fully human antibodies to shuttle drugs past the blood-brain barrier, a move that could unlock a new era of treatments.

Immunomic Therapeutics begins human trials for ITI-9001, an saRNA vaccine aiming to rewrite the immune response to Japanese cedar pollen allergy.

New data reveals a deep divide in who can access revolutionary weight-loss drugs, exposing a market that is both booming and profoundly under-penetrated.

An inside look at how Chengdu is pairing high-tech industrial might with aggressive global outreach to redefine itself as a critical node in tech and biotech.

New guidelines for ankle arthritis, a condition hitting younger workers hard, expose major gaps in medical research and a market ripe for innovation.

At Boston's Wedbush Renal Summit, Hansa Biopharma showcases its game-changing transplant drug, signaling a major strategic play for the lucrative U.S. market.

A massive financing round for deupirfenidone isn't just about a potential new IPF drug; it's a masterclass in biotech strategy, validating a model that promises value for all.

Michael Goettler leaves the Bausch Health board to lead Knoa Pharma, a firm born from Purdue's ashes. A look at the strategic move shaking up pharma.

A new study for CRENESSITY could revolutionize care for infants with classic congenital adrenal hyperplasia, shifting the treatment paradigm and solidifying market leadership.

Advicenne's unlimited UK drug approval for Sibnayal® is a win for rare disease patients, but it's one piece in a high-stakes global strategy now targeting the US market.

Rentschler Biopharma appoints Dr. Torsten Woehr as CEO, a strategic move to deepen its core biologics focus after exiting cell and gene therapy.

As lawsuits allege a link between blockbuster weight-loss drugs like Ozempic and irreversible blindness, a critical question emerges: Who guards our health?

A surge in biotech innovation is set to transform the high-grade glioma market. With a pipeline of targeted drugs and vaccines, a once-stagnant field is now a beacon of hope.

Oryzon Genomics secures a dual funding package, navigating market jitters to accelerate its pioneering cancer and psychiatric drug pipelines with EU backing.

Artelo's latest data on its non-opioid pain drug ART26.12 could unlock a massive market, but what are the real risks and rewards for this clinical-stage biotech?

Vyome Holdings secures a key patent in China, not by betting the farm, but by making a shrewd, capital-efficient move to tap into a massive future market.